Which has stronger earnings & valuation, ALZN or CLRB?

Alzamend Neuro is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alzamend Neuro N/A N/A -$4.51M -$2.16 N/A Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A

Is ALZN or CLRB more profitable?

Alzamend Neuro's return on equity of -177.52% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Alzamend Neuro N/A -177.52% -140.41% Cellectar Biosciences N/A -349.24% -153.18%

Which has stronger earnings & valuation, ALZN or SNSE?

Alzamend Neuro is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alzamend Neuro N/A N/A -$4.51M -$2.16 N/A Sensei Biotherapeutics N/A N/A -$21.08M -$142.72 N/A

Is ALZN or SNSE more profitable?

Sensei Biotherapeutics' return on equity of -83.59% beat Alzamend Neuro's return on equity. Company Net Margins Return on Equity Return on Assets Alzamend Neuro N/A -177.52% -140.41% Sensei Biotherapeutics N/A -83.59% -256.50%

Do analysts prefer ALZN or TPST?

Alzamend Neuro currently has a consensus price target of $28.00, suggesting a potential upside of 2,233.33%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, research analysts plainly believe Alzamend Neuro is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alzamend Neuro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher earnings & valuation, ALZN or TPST?

Alzamend Neuro is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alzamend Neuro N/A N/A -$4.51M -$2.16 N/A Tempest Therapeutics N/A N/A -$26.26M -$6.01 N/A

Is ALZN or TPST more profitable?

Alzamend Neuro's return on equity of -177.52% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alzamend Neuro N/A -177.52% -140.41% Tempest Therapeutics N/A -355.61% -121.21%

Which has preferable valuation & earnings, ALZN or MDCX?

Alzamend Neuro is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alzamend Neuro N/A N/A -$4.51M -$2.16 N/A Medicus Pharma N/A N/A -$35.46M -$2.68 N/A

Is ALZN or MDCX more profitable?

Alzamend Neuro's return on equity of -177.52% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Alzamend Neuro N/A -177.52% -140.41% Medicus Pharma N/A -3,137.84% -311.33%

Do analysts rate ALZN or XCUR?

Alzamend Neuro presently has a consensus price target of $28.00, suggesting a potential upside of 2,233.33%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, research analysts clearly believe Alzamend Neuro is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alzamend Neuro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, ALZN or XCUR?

Exicure is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alzamend Neuro N/A N/A -$4.51M -$2.16 N/A Exicure N/A N/A -$4.95M -$1.55 N/A

Is ALZN or XCUR more profitable?

Alzamend Neuro's return on equity of -177.52% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Alzamend Neuro N/A -177.52% -140.41% Exicure N/A -179.41% -64.37%

Alzamend Neuro (ALZN) Competitors

$1.20 +0.04 (+3.45%)

As of 11:48 AM Eastern

Compare

ALZN vs. CLRB, SNSE, TPST, MDCX, and XCUR

Should you buy Alzamend Neuro stock or one of its competitors? MarketBeat compares Alzamend Neuro with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alzamend Neuro include Cellectar Biosciences (CLRB), Sensei Biotherapeutics (SNSE), Tempest Therapeutics (TPST), Medicus Pharma (MDCX), and Exicure (XCUR). These companies are all part of the "pharmaceutical products" industry.

How does Alzamend Neuro compare to Cellectar Biosciences?

Alzamend Neuro (NASDAQ:ALZN) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Alzamend Neuro presently has a consensus target price of $28.00, suggesting a potential upside of 2,233.33%. Cellectar Biosciences has a consensus target price of $11.00, suggesting a potential upside of 311.21%. Given Alzamend Neuro's higher possible upside, analysts plainly believe Alzamend Neuro is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Alzamend Neuro has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

Alzamend Neuro is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

Alzamend Neuro's return on equity of -177.52% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-177.52%	-140.41%
Cellectar Biosciences	N/A	-349.24%	-153.18%

In the previous week, Cellectar Biosciences had 2 more articles in the media than Alzamend Neuro. MarketBeat recorded 3 mentions for Cellectar Biosciences and 1 mentions for Alzamend Neuro. Alzamend Neuro's average media sentiment score of 1.87 beat Cellectar Biosciences' score of 1.16 indicating that Alzamend Neuro is being referred to more favorably in the media.

Company	Overall Sentiment
Alzamend Neuro	Very Positive
Cellectar Biosciences	Positive

49.6% of Alzamend Neuro shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by insiders. Comparatively, 2.6% of Cellectar Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Alzamend Neuro beats Cellectar Biosciences on 7 of the 13 factors compared between the two stocks.

How does Alzamend Neuro compare to Sensei Biotherapeutics?

Alzamend Neuro (NASDAQ:ALZN) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Sensei Biotherapeutics' return on equity of -83.59% beat Alzamend Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-177.52%	-140.41%
Sensei Biotherapeutics	N/A	-83.59%	-256.50%

Alzamend Neuro has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.25, suggesting that its share price is 125% less volatile than the broader market.

49.6% of Alzamend Neuro shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Alzamend Neuro currently has a consensus target price of $28.00, suggesting a potential upside of 2,233.33%. Sensei Biotherapeutics has a consensus target price of $48.00, suggesting a potential upside of 239.34%. Given Alzamend Neuro's higher possible upside, equities research analysts plainly believe Alzamend Neuro is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Alzamend Neuro is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A

In the previous week, Alzamend Neuro and Alzamend Neuro both had 1 articles in the media. Alzamend Neuro's average media sentiment score of 1.87 equaled Sensei Biotherapeutics'average media sentiment score.

Company	Overall Sentiment
Alzamend Neuro	Very Positive
Sensei Biotherapeutics	Very Positive

Summary

Alzamend Neuro beats Sensei Biotherapeutics on 6 of the 11 factors compared between the two stocks.

How does Alzamend Neuro compare to Tempest Therapeutics?

Alzamend Neuro (NASDAQ:ALZN) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Alzamend Neuro has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.85, suggesting that its share price is 285% less volatile than the broader market.

Alzamend Neuro's return on equity of -177.52% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-177.52%	-140.41%
Tempest Therapeutics	N/A	-355.61%	-121.21%

Alzamend Neuro currently has a consensus price target of $28.00, suggesting a potential upside of 2,233.33%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, research analysts plainly believe Alzamend Neuro is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Alzamend Neuro is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A

49.6% of Alzamend Neuro shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by company insiders. Comparatively, 36.3% of Tempest Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Tempest Therapeutics had 1 more articles in the media than Alzamend Neuro. MarketBeat recorded 2 mentions for Tempest Therapeutics and 1 mentions for Alzamend Neuro. Alzamend Neuro's average media sentiment score of 1.87 beat Tempest Therapeutics' score of 1.43 indicating that Alzamend Neuro is being referred to more favorably in the media.

Company	Overall Sentiment
Alzamend Neuro	Very Positive
Tempest Therapeutics	Positive

Summary

Alzamend Neuro beats Tempest Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Alzamend Neuro compare to Medicus Pharma?

Alzamend Neuro (NASDAQ:ALZN) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

In the previous week, Medicus Pharma had 2 more articles in the media than Alzamend Neuro. MarketBeat recorded 3 mentions for Medicus Pharma and 1 mentions for Alzamend Neuro. Alzamend Neuro's average media sentiment score of 1.87 beat Medicus Pharma's score of 1.43 indicating that Alzamend Neuro is being referred to more favorably in the media.

Company	Overall Sentiment
Alzamend Neuro	Very Positive
Medicus Pharma	Positive

49.6% of Alzamend Neuro shares are held by institutional investors. 1.4% of Alzamend Neuro shares are held by insiders. Comparatively, 8.1% of Medicus Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Alzamend Neuro's return on equity of -177.52% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-177.52%	-140.41%
Medicus Pharma	N/A	-3,137.84%	-311.33%

Alzamend Neuro has a beta of 0.16, suggesting that its stock price is 84% less volatile than the broader market. Comparatively, Medicus Pharma has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market.

Alzamend Neuro presently has a consensus target price of $28.00, suggesting a potential upside of 2,233.33%. Medicus Pharma has a consensus target price of $9.00, suggesting a potential upside of 1,959.50%. Given Alzamend Neuro's higher possible upside, analysts clearly believe Alzamend Neuro is more favorable than Medicus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Alzamend Neuro is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

Summary

Alzamend Neuro beats Medicus Pharma on 8 of the 13 factors compared between the two stocks.

How does Alzamend Neuro compare to Exicure?

Alzamend Neuro (NASDAQ:ALZN) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Alzamend Neuro presently has a consensus price target of $28.00, suggesting a potential upside of 2,233.33%. Given Alzamend Neuro's stronger consensus rating and higher probable upside, research analysts clearly believe Alzamend Neuro is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alzamend Neuro	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Exicure had 1 more articles in the media than Alzamend Neuro. MarketBeat recorded 2 mentions for Exicure and 1 mentions for Alzamend Neuro. Exicure's average media sentiment score of 1.89 beat Alzamend Neuro's score of 1.87 indicating that Exicure is being referred to more favorably in the news media.

Company	Overall Sentiment
Alzamend Neuro	Very Positive
Exicure	Very Positive

Alzamend Neuro has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market. Comparatively, Exicure has a beta of 3.53, indicating that its stock price is 253% more volatile than the broader market.

49.6% of Alzamend Neuro shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 1.4% of Alzamend Neuro shares are owned by company insiders. Comparatively, 52.8% of Exicure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Alzamend Neuro's return on equity of -177.52% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alzamend Neuro	N/A	-177.52%	-140.41%
Exicure	N/A	-179.41%	-64.37%

Exicure is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alzamend Neuro	N/A	N/A	-$4.51M	-$2.16	N/A
Exicure	N/A	N/A	-$4.95M	-$1.55	N/A

Summary

Alzamend Neuro beats Exicure on 7 of the 13 factors compared between the two stocks.

Get Alzamend Neuro News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALZN vs. The Competition

Export

Metric	Alzamend Neuro	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.57M	$3.64B	$6.76B	$12.51B
Dividend Yield	N/A	2.21%	2.66%	6.22%
P/E Ratio	-0.56	21.05	25.78	24.73
Price / Sales	N/A	343.87	548.02	103.35
Price / Cash	N/A	62.10	29.14	36.96
Price / Book	0.24	8.74	10.84	6.52
Net Income	-$4.51M	$23.81M	$3.57B	$336.86M
7 Day Performance	-12.41%	3.68%	2.43%	1.31%
1 Month Performance	0.84%	1.64%	0.76%	0.36%
1 Year Performance	-58.76%	69.92%	36.68%	30.89%

Alzamend Neuro Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALZN Alzamend Neuro	4.3008 of 5 stars	$1.20 +3.4%	$28.00 +2,233.3%	-60.0%	$4.57M	N/A	N/A	4	Positive News Gap Down
CLRB Cellectar Biosciences	4.5284 of 5 stars	$2.45 +4.7%	$11.00 +349.0%	-67.1%	$18.70M	N/A	N/A	10	Positive News Short Interest Decrease
SNSE Sensei Biotherapeutics	3.7141 of 5 stars	$14.15 +2.1%	$48.00 +239.3%	+64.3%	$18.59M	N/A	N/A	40	Positive News Gap Up High Trading Volume
TPST Tempest Therapeutics	1.9313 of 5 stars	$1.25 flat	N/A	-84.1%	$18.51M	N/A	N/A	20	Positive News Short Interest Decrease
MDCX Medicus Pharma	3.7104 of 5 stars	$0.33 +4.7%	$9.00 +2,587.4%	-83.2%	$18.13M	N/A	N/A	N/A	Positive News Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALZN) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alzamend Neuro (ALZN) Competitors

ALZN vs. CLRB, SNSE, TPST, MDCX, and XCUR

How does Alzamend Neuro compare to Cellectar Biosciences?

Summary

How does Alzamend Neuro compare to Sensei Biotherapeutics?

Summary

How does Alzamend Neuro compare to Tempest Therapeutics?

Summary

How does Alzamend Neuro compare to Medicus Pharma?

Summary

How does Alzamend Neuro compare to Exicure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN vs. The Competition

Alzamend Neuro Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alzamend Neuro (ALZN) Competitors

ALZN vs. CLRB, SNSE, TPST, MDCX, and XCUR

How does Alzamend Neuro compare to Cellectar Biosciences?

Do analysts recommend ALZN or CLRB?

Which has more volatility and risk, ALZN or CLRB?

Which has stronger earnings & valuation, ALZN or CLRB?

Is ALZN or CLRB more profitable?

Does the media refer more to ALZN or CLRB?

Do institutionals and insiders have more ownership in ALZN or CLRB?

Summary

How does Alzamend Neuro compare to Sensei Biotherapeutics?

Is ALZN or SNSE more profitable?

Which has more volatility and risk, ALZN or SNSE?

Do insiders & institutionals hold more shares of ALZN or SNSE?

Do analysts rate ALZN or SNSE?

Which has stronger earnings & valuation, ALZN or SNSE?

Does the media prefer ALZN or SNSE?

Summary

How does Alzamend Neuro compare to Tempest Therapeutics?

Which has more risk & volatility, ALZN or TPST?

Is ALZN or TPST more profitable?

Do analysts prefer ALZN or TPST?

Which has higher earnings & valuation, ALZN or TPST?

Do institutionals & insiders hold more shares of ALZN or TPST?

Does the media refer more to ALZN or TPST?

Summary

How does Alzamend Neuro compare to Medicus Pharma?

Does the media refer more to ALZN or MDCX?

Do institutionals and insiders believe in ALZN or MDCX?

Is ALZN or MDCX more profitable?

Which has more volatility & risk, ALZN or MDCX?

Do analysts prefer ALZN or MDCX?

Which has preferable valuation & earnings, ALZN or MDCX?

Summary

How does Alzamend Neuro compare to Exicure?

Do analysts rate ALZN or XCUR?

Does the media refer more to ALZN or XCUR?

Which has more risk and volatility, ALZN or XCUR?

Do institutionals & insiders hold more shares of ALZN or XCUR?

Is ALZN or XCUR more profitable?

Which has stronger earnings & valuation, ALZN or XCUR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALZN vs. The Competition

Alzamend Neuro Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools